ALPS Advisors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

ALPS Advisors’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-63,109	Closed	-$2.13M	–	1063
2021 Q2	$2.13M	Sell	63,109 -23,468	-27%	-$598K	0.02%	315
2021 Q1	$2.02M	Buy	86,577 +721	+0.8%	+$21.8K	0.02%	292
2020 Q4	$2.47M	Buy	85,856 +25,283	+42%	+$636K	0.03%	245
2020 Q3	$1.23M	Buy	60,573 +3,505	+6%	+$85.6K	0.02%	313
2020 Q2	$1.72M	Sell	57,068 -15,720	-22%	-$566K	0.02%	253
2020 Q1	$2.29M	Buy	72,788 +5,210	+8%	+$181K	0.04%	203
2019 Q4	$3.18M	Buy	67,578 +16,117	+31%	+$465K	0.02%	190
2019 Q3	$332K	Sell	51,461 -2,539	-5%	-$21.2K	﹤0.01%	798
2019 Q2	$663K	Buy	+54,000	New	+$601K	﹤0.01%	477

ALPS Advisors's CNST Position: Q3 2021 in Review

ALPS Advisors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 63,109 shares — an estimated $2.13M sold.

ALPS Advisors first reported a position in CNST in Q2 2019 and held it in 9 quarters. The position peaked at $3.18M in Q4 2019. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

ALPS Advisors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
ALPS Advisors sold 63,109 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $2.13M.
ALPS Advisors first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2019 and held it in 9 quarters.
ALPS Advisors's Constellation Pharmaceuticals, Inc. position peaked at $3.18M in Q4 2019.
0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on ALPS Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.